| Literature DB >> 24308642 |
Shauna M Downs, Vidhu Gupta, Suparna Ghosh-Jerath, Karen Lock, Anne Marie Thow, Archna Singh1.
Abstract
BACKGROUND: The consumption of partially hydrogenated vegetable oils (PHVOs) high in trans fat is associated with an increased risk of cardiovascular disease and other non-communicable diseases. In response to high intakes of PHVOs, the Indian government has proposed regulation to set limits on the amount of trans fat permissible in PHVOs. Global recommendations are to replace PHVOs with polyunsaturated fatty acids (PUFAs) in order to optimise health benefits; however, little is known about the practicalities of implementation in low-income settings. The aim of this study was to examine the technical and economic feasibility of reducing trans fat in PHVOs and reformulating it using healthier fats.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24308642 PMCID: PMC3878993 DOI: 10.1186/1471-2458-13-1139
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Interview topics based on technical and economic feasibility of reformulating partially hydrogenated vegetable oils in India
| Trans fat and health | What is your understanding of the health issues related to – |
| Company characteristics | What are the main products that your company produces? |
| | Which of the products that your company produces contain hydrogenated oils? |
| | Where do you obtain your raw materials? (which areas, types of producers)? |
| Trans fat regulation | What do you know about the proposed trans fat regulation? |
| | How will the proposed trans fat regulation affect your company? Will it affect your profit margins? |
| | Could the government do anything to help (i.e., incentives, subsidies, etc.) make the transition to low trans/trans fat free products easier? |
| Feasibility | How feasible is product reformulation of |
| | Can you comment on the: |
| | Technological feasibility |
| | Availability of replacement oils |
| | Economic feasibility |
| | What considerations will have to be made in terms of the cultural/social acceptability of alternative products? |
| | What will be the main barriers or challenges associated with product reformulation? |
| Costs | What are the current costs associated with the production of |
| | Which additional costs will be involved in the reformulation of |
| How will these costs differ with a limit of 10% vs 5% trans fat in PHVOs? |
Supporting quotes related to regulatory issues for manufacturing
| Lengthy policy process | “We have always seen that any regulation change in India takes little longer and we have…this both famous and infamous process of far too much consultations”. |
| Melting point regulation | “I am forced to incorporate trans [fat] into my product…as a technical person I know that the trans [fat] is not good and the whole world is moving towards not having trans but I am forced to do that”. |
Supporting quotes relating to the replacement oils for product reformulation
| Use of palm oil | “The main raw material is 90-95% only palm oil. There [is] no other option because indigenous oil prices are very high”. |
| Palm oil import | “The major players they have shifted their production to Kandla itself, the importing place [for palm oil], because they have got the benefit of the logistic so they can have [a] better price, manufacturing cost and all that”. |
Supporting quotes describing the economic feasibility of product reformulation
| Reducing costs of vanaspati | “Business is so competitive, everybody has to be on their toes to cut down the cost”. |
| | “People have already started using this [palm] stearin…so the unscrupulous people they are selling at a very low price…we can’t play with the health of the people so we better decide to stop the production [of vanaspati]”. |
| Industry capacity | “They [government] talk about trans [fat] reducing, trans [fat] reducing, trans [fat] reducing but…they are not looking at the holistic picture of what it means for the industry to cope with that”. |
| Compliance with regulation | “If someone is not doing it…we should not make people suffer from the health point of view - let bigger companies start [complying with the regulation]”. |